BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8058314)

  • 1. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
    Zhang W; Guo XY; Deisseroth AB
    Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
    Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
    Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel DNA binding of p53 mutants and their role in transcriptional activation.
    Zhang W; Funk WD; Wright WE; Shay JW; Deisseroth AB
    Oncogene; 1993 Sep; 8(9):2555-9. PubMed ID: 8361764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its antiproliferation function.
    Zhang W; Randhawa GS; Guo XY; Deisseroth AB
    Cell Growth Differ; 1994 Jul; 5(7):705-10. PubMed ID: 7947385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
    Zhang W; Shay JW; Deisseroth A
    Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of p53 DNA binding activity by point mutation.
    Marston NJ; Ludwig RL; Vousden KH
    Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential.
    Mundt M; Hupp T; Fritsche M; Merkle C; Hansen S; Lane D; Groner B
    Oncogene; 1997 Jul; 15(2):237-44. PubMed ID: 9244359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
    Shivakumar CV; Das GC
    Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct regions of p53 have a differential role in transcriptional activation and repression functions.
    Sang BC; Chen JY; Minna J; Barbosa MS
    Oncogene; 1994 Mar; 9(3):853-9. PubMed ID: 8108128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analysis of p53: the acidic activation domain has transforming capability.
    Hulboy DL; Lozano G
    Cell Growth Differ; 1994 Oct; 5(10):1023-31. PubMed ID: 7848903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
    Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
    Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
    Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
    Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling to p53: breaking the posttranslational modification code.
    Appella E; Anderson CW
    Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 transactivation through various p53-responsive elements.
    Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
    Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.